DARK SECRETS: 3 - The Real Truth

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Barchart · Sep 1, 2025

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga · Aug 25, 2025

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga · Aug 6, 2025

Dow Leads as Merck, Amgen Gain: Stock Market Today

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.

Kiplinger · Jul 22, 2025

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Barchart · Jul 16, 2025

Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades'

As Wall Street looks ahead to the July 4 holiday weekend, a wave of optimism ripples through the trading floor, with seasoned investors poised to capitalize on emerging opportunities.

Benzinga · Jul 3, 2025

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

AAP · Jun 26, 2025

Microsoft Copilot is "pretty important" but customers still prefer ChatGPT — "OpenAI has done a tremendous job"

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

Windows Central · Jun 25, 2025

New once-a-month drug could treat diabetes and obesity, scientists say

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

The Independent UK · Jun 24, 2025

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

Benzinga · Jun 23, 2025